BioSpace News Archive

Drug Development

Reata Announces First Patient Enrolled in Part II of MOXIe Study of Omaveloxolone for the Treatment of Friedreich’s Ataxia

The trial will enroll approximately 100 FA patients randomized evenly to either 150 mg of omaveloxolone or placebo.

October 23, 2017

·

4 min read

Business

Akcea Therapeutics to Hold Third Quarter 2017 Financial Results Webcast

The company will host a live webcast on Monday, November 6 at 4:30 p.m. Eastern Time to discuss its third quarter 2017 financial results.

October 23, 2017

·

3 min read

Business

Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines

This awarded grant is part of BARDA’s Advance Development of Medical Countermeasures for Pandemic Influenza, which focuses on improving the government’s responsiveness to future pandemic threats.

October 23, 2017

·

2 min read

Policy

MannKind and BIOMM Submit Registration Dossier to Brazilian Health Regulatory Agency (ANVISA)

Afrezza is the only inhaled rapid-acting mealtime insulin approved by the U.S. Food & Drug Administration.

October 23, 2017

·

4 min read

Biotech Beach

MannKind Restructures Near-Term Debt Obligations

MannKind entered into an exchange agreement with the holders of its outstanding 5.75% Convertible Senior Subordinated Exchange Notes due 2018.

October 23, 2017

·

6 min read

Business

Queen’s University Belfast in Collaboration with Almac Group Lead Largest Study of its Kind to Transform Prostate Cancer Treatment

Queen’s University Belfast have led the world’s largest research study using a diagnostic test developed by Almac Diagnostics, to better understand the biology of prostate cancer tumours.

October 23, 2017

·

4 min read

Pharm Country

Immune Pharmaceuticals Inc. Announces Closing of $18,000,000 Public Offering of Convertible Preferred Stock and Warrants

Immune Pharmaceuticals Inc. announced the closing of its previously announced public offering of units for gross proceeds of $18,000,000, which excludes underwriting discounts and commissions and offering expenses payable by Immune.

October 23, 2017

·

4 min read

Cesar Millan helps Avivagen Relaunch Vivamune Health Chews in U.S.

At the heart of Vivamune is an active substance, called OxC-beta (OxC-beta) compound, Avivagen’s proprietary formulation of fully oxidized β-carotene.

October 23, 2017

·

6 min read

Business

VBL Therapeutics Celebrates Opening of its New Gene Therapy Manufacturing Plant and Company Headquarters

This plant will be the commercial facility for production of the Company’s lead product candidate, ofranergene obadenovec (VB-111), if approved.

October 23, 2017

·

6 min read

Business

Recipharm Equips Lisbon Facility for US and European Serialisation

Recipharm, a leading contract development and manufacturing organisation (CDMO) has equipped its sixth facility with serialisation capabilities ahead of the US and European regulation enforcement deadlines.

October 23, 2017

·

3 min read